Experts spotlight the variety of breast cancer research being presented at the 2026 ESMO Congress.
Commentary|Articles|December 4, 2025
Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Leading experts highlight key HER2-positive studies ahead of SABCS 2025.
Advertisement
Advertisement
As anticipation builds for this year’s San Antonio Breast Cancer Symposium (SABCS), OncLive® asked leading breast cancer specialists to share the HER2-positive research topics they are most eager to follow at this year’s meeting.
Related to this article
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.
The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.
Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
Advertisement
Advertisement